Eli Lilly Hits All-Time High Above $1,293 as Goldman Sachs Raises Price Target to $1,413

Eli Lilly shares surged roughly 4-5% on October 20 to a record high of $1,293.11, with the stock adding approximately $41 billion in market value in a single session and pushing the company's valuation past Berkshire Hathaway ahead of its third-quarter earnings report. The rally made Lilly the top value creator in the S&P 500 on the day, as the broader healthcare sector hit record highs and led all eleven S&P 500 sectors.

Two catalysts drove the move. Goldman Sachs raised its price target on the stock to $1,413 from a lower prior figure while maintaining a Buy rating, citing potential upside in Lilly's position in the weight-loss drug market. Separately, a European regulatory endorsement for Foundayo, an oral obesity pill, added momentum, reinforcing the company's competitive standing against rival Novo Nordisk in the rapidly expanding GLP-1 market.

Lilly's most recent quarterly results showed revenue growth of 47.7%, though analysts anticipate a decline in earnings per share as competition and market dynamics weigh on margins. Over a five-year span, Lilly shares have risen 431%, ranking it among the top five performers in the largest U.S.-listed companies alongside Nvidia, Micron, Palantir, and Broadcom. On the institutional side, BDF Gestion trimmed its position by 11.3% in the third quarter, selling 2,030 shares to leave a remaining stake of 16,004 shares.